ID: ALA4877066

Max Phase: Preclinical

Molecular Formula: C194H307N53O59S2

Molecular Weight: 4390.04

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O

Standard InChI:  InChI=1S/C194H307N53O59S2/c1-19-100(10)152(185(297)232-129(75-98(6)7)190(302)247-72-48-58-138(247)191(303)246-71-47-57-137(246)183(295)242-156(107(17)254)188(300)231-128(84-144(201)261)174(286)237-151(99(8)9)184(296)208-87-147(264)217-130(89-248)177(289)229-127(83-143(200)260)176(288)243-157(108(18)255)192(304)245-70-45-55-135(245)158(202)270)238-182(294)136-56-46-69-244(136)148(265)88-209-162(274)120(76-109-49-36-34-37-50-109)223-172(284)124(80-140(197)257)227-173(285)125(81-141(198)258)228-178(290)131(90-249)234-179(291)132(91-250)233-171(283)123(79-112-86-206-95-211-112)226-170(282)122(78-111-85-205-94-210-111)225-168(280)119(74-97(4)5)222-169(281)121(77-110-51-38-35-39-52-110)224-166(278)116(63-66-150(268)269)218-159(271)101(11)212-167(279)118(73-96(2)3)221-164(276)114(54-44-68-207-194(203)204)219-165(277)115(61-64-139(196)256)220-187(299)154(105(15)252)239-160(272)102(12)213-180(292)133-92-307-308-93-134(181(293)230-126(82-142(199)259)175(287)241-153(104(14)251)186(298)214-103(13)161(273)240-155(106(16)253)189(301)236-133)235-163(275)113(53-42-43-67-195)215-146(263)65-62-117(193(305)306)216-145(262)59-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-60-149(266)267/h34-39,49-52,85-86,94-108,113-138,151-157,248-255H,19-33,40-48,53-84,87-93,195H2,1-18H3,(H2,196,256)(H2,197,257)(H2,198,258)(H2,199,259)(H2,200,260)(H2,201,261)(H2,202,270)(H,205,210)(H,206,211)(H,208,296)(H,209,274)(H,212,279)(H,213,292)(H,214,298)(H,215,263)(H,216,262)(H,217,264)(H,218,271)(H,219,277)(H,220,299)(H,221,276)(H,222,281)(H,223,284)(H,224,278)(H,225,280)(H,226,282)(H,227,285)(H,228,290)(H,229,289)(H,230,293)(H,231,300)(H,232,297)(H,233,283)(H,234,291)(H,235,275)(H,236,301)(H,237,286)(H,238,294)(H,239,272)(H,240,273)(H,241,287)(H,242,295)(H,243,288)(H,266,267)(H,268,269)(H,305,306)(H4,203,204,207)/t100-,101-,102-,103-,104+,105+,106+,107+,108+,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,151-,152-,153-,154-,155-,156-,157-/m0/s1

Standard InChI Key:  RKBAMGVDUHMLBI-WRKJJXHBSA-N

Associated Targets(Human)

INS Tbio Insulin (123 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 4390.04Molecular Weight (Monoisotopic): 4387.2093AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K..  (2021)  Development of Cagrilintide, a Long-Acting Amylin Analogue.,  64  (15.0): [PMID:34288673] [10.1021/acs.jmedchem.1c00565]

Source